Evidence map›Paper›PMID 36766710›Full record

ArticleCells2023

Systemically Identifying Triple-Negative Breast Cancer Subtype-Specific Prognosis Signatures, Based on Single-Cell RNA-Seq Data.

Kaiyuan Xing, Bo Zhang, Zixuan Wang, Yanru Zhang, Tengyue Chai, Jingkai Geng, Xuexue Qin, Xi Steven Chen, Xinxin Zhang, Chaohan Xu

Open access · goldAbstract read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Kaiyuan XingCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Bo ZhangDepartment of Pharmacology, State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, College of Pharmacy, Harbin Medical University, Harbin 150081, China.
Zixuan WangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Yanru ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Tengyue ChaiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Jingkai GengCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Xuexue QinCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Xi Steven ChenDepartment of Public Health Sciences, Division of Biostatistics, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Xinxin ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Chaohan XuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China.
Harbin Medical University · CNUniversity of Miami · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is a highly heterogeneous disease with different molecular subtypes. Although progress has been made, the identification of TNBC subtype-associated biomarkers is still hindered by traditional RNA-seq or array technologies, since bulk data detected by them usually have some non-disease tissue samples, or they are confined to measure the averaged properties of whole tissues. To overcome these constraints and discover TNBC subtype-specific prognosis signatures (TSPSigs), we proposed a single-cell RNA-seq-based bioinformatics approach for identifying TSPSigs. Notably, the TSPSigs we developed mostly were found to be disease-related and involved in cancer development through investigating their enrichment analysis results. In addition, the prognostic power of TSPSigs was successfully confirmed in four independent validation datasets. The multivariate analysis results showed that TSPSigs in two TNBC subtypes-BL1 and LAR, were two independent prognostic factors. Further, analysis results of the TNBC cell lines revealed that the TSPSigs expressions and drug sensitivities had significant associations. Based on the preceding data, we concluded that TSPSigs could be exploited as novel candidate prognostic markers for TNBC patients and applied to individualized treatment in the future.

Indexed as

Triple Negative Breast NeoplasmsBiomarkers, TumorComputational BiologyHumansMultivariate AnalysisSingle-Cell Gene Expression AnalysisBiomarkers, Tumorprognosis signaturesingle-cell RNA-seqTNBC subtype-specific

Identifiers

PMID36766710
PMCPMC9913740
OpenAlexW4317517570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.